文献速递消化系统肿瘤

原发肿瘤部位与FOLFOXIRI联合贝伐珠单抗一线治疗转移性结直肠癌的获益:TRIBE试验的GONO回顾性分析

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.
PubMed 文献 · Ann Oncol · 2018-04-20

该研究为TRIBE试验的非计划分析,纳入358例有原发部位及RAS/BRAF状态的转移性结直肠癌患者,比较FOLFIRI+贝伐珠单抗与FOLFOXIRI+贝伐珠单抗。右侧肿瘤患者OS较短,但调整RAS/BRAF后关联消失;右侧患者从化疗强化中获益更明显,且不依赖RAS/BRAF状态。

要点

  • 右侧转移性结直肠癌患者预后较差,OS显著缩短。
  • 右侧患者从FOLFOXIRI+贝伐珠单抗强化化疗中获益更明显。
  • 该获益独立于RAS和BRAF突变状态。

核心结论

  • FOLFOXIRI联合贝伐珠单抗可作为经临床选择的右侧转移性结直肠癌患者优选一线方案,无论RAS和BRAF状态。

研究设计与样本

  • TRIBE试验的非计划回顾性分析,纳入358例有原发部位及RAS/BRAF信息的随机患者。
  • 患者随机接受FOLFIRI+贝伐珠单抗或FOLFOXIRI+贝伐珠单抗一线治疗。

主要发现

  • 右侧肿瘤患者(N=173)中位OS为23.7个月,左侧(N=185)为31.0个月,HR=1.42(95%CI 1.09-1.84),P=0.010。
  • 右侧肿瘤患者中位PFS为10.2个月,左侧为11.5个月,HR=1.24(95%CI 0.98-1.56),P=0.083。
  • 调整RAS和BRAF状态后,原发部位与OS/PFS的关联不再显著。
  • 右侧患者化疗强化对PFS的HR=0.59 vs 0.89,交互P=0.099;对OS的HR=0.56 vs 0.99,交互P=0.030。
  • 化疗强化获益独立于RAS和BRAF状态。

临床怎么用

  • 对临床选择的右侧转移性结直肠癌患者,可优先考虑FOLFOXIRI+贝伐珠单抗一线治疗。
  • 决策时无需依据RAS或BRAF状态筛选化疗强化获益人群。

局限性

  • 为非计划回顾性分析,仅纳入70.5%的随机患者(358/508)。
  • 原发部位预后影响在调整RAS/BRAF后消失,提示存在混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Right-sided metastatic colorectal cancer (mCRC) patients have poor prognosis and achieve limited benefit from first-line doublets plus a targeted agent. In this unplanned analysis of the TRIBE study, we investigated the prognostic and predictive impact of primary tumor sidedness in mCRC patients and the differential impact of the intensification of the chemotherapy in subgroups defined according to both primary tumor sidedness and RAS and BRAF mutational status. PATIENTS AND METHODS: Patients were randomized to receive upfront 5-fluoruracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab or 5-fluoruracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab. Tumors were defined as right- or left-sided if they originated from the caecum to the transverse colon or within the splenic flexure and beyond, respectively. Patients with available information about both primary sidedness and RAS and BRAF status were included in the present analysis. Progression-free survival (PFS), overall survival (OS) and RECIST response rate were assessed according to tumor location and RAS and BRAF mutational status. RESULTS: Information about primary sidedness and RAS and BRAF status was available for 358 (70.5%) out of 508 randomized patients. Patients with right-sided tumors (N = 173) presented shorter OS [23.7 versus 31.0 months, HR = 1.42 (95% CI 1.09-1.84), P = 0.010] and a trend toward shorter PFS [10.2 versus 11.5 months, HR = 1.24 (95% CI: 0.98-1.56), P = 0.083] than those with left-sided tumors (N = 185), but these associations were no longer evident when adjusting for RAS and BRAF status. Patients with right-sided tumors achieved more relative benefit from the intensification of the chemotherapy backbone in terms of both PFS (HR = 0.59 versus 0.89, P for interaction = 0.099) and OS (HR = 0.56 versus 0.99, P for interaction = 0.030) and this advantage was independent of their RAS and BRAF status. CONCLUSIONS: FOLFOXIRI plus bevacizumab may be regarded as a preferred first-line treatment option for clinically selected patients with right-sided metastatic colorectal cancer irrespective of their RAS and BRAF mutational status. Trial registration: clinicaltrials.gov identifier NCT00719797.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Cremolini C, Antoniotti C, Lonardi S, et al. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Ann Oncol. 2018. PMID: 29873679. doi:10.1093/annonc/mdy140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。